Infographic: Investment Opportunities in Biotech | Canada News Media
Connect with us

Investment

Infographic: Investment Opportunities in Biotech

Published

 on

Graphics & Design

Infographic: Investment Opportunities in Biotech

With the world evolving at an unprecedented pace, nearly every sector is being disrupted in some way or another.

In transportation, EVs were spearheaded by Tesla, which emerged as the first new American automaker in decades, and is now one of the world’s most valuable companies. Similarly, in the realm of AI, OpenAI has taken a leading position in large language models, demonstrating the immense potential of the technology.

Now, we turn our attention to biotech, an industry that is developing innovative treatments at an accelerated pace. In this graphic from sponsor MSCI, we explain the growing pipeline of biotech treatments, and why this could benefit investors.

Growth in Clinical Drug Trials

A clinical drug trial is a study performed on people to evaluate the effectiveness of a medical intervention. Since 2000, the number of trials initiated annually has grown by over 1,300%.

Drug Trial Type 2000 2010 2020 2022
Monoclonal antibody 60 623 1,833 1,685
Protein & peptide therapeutics 172 1,058 1,771 1,567
Vaccine 80 594 1,259 915
Recombinant antibody 50 513 984 860
Cell therapy 56 277 548 502
Gene-Modified Cell Therapy 16 148 355 423
DNA & RNA therapeutics 7 56 475 346
Other biotechnology product 28 236 362 347
Total 469 3,505 7,587 6,645

Behind every new treatment is an innovative company working to develop it. Thus, as the number of clinical trials grows, so too does the size of the investment universe.

Unfortunately, identifying suitable companies for investment is rather difficult. While a disease may have thousands of potential medicines, only one may ultimately receive FDA approval. This approval process can also take over a decade because treatments must pass several phases of testing.

Introducing the MSCI Life Sciences Indexes

To capture investment opportunities in biotech, MSCI has released a suite of thematic indexes that focus on key growth categories such as oncology and virology.

Developed in collaboration with Royalty Pharma, the world’s largest buyer of pharmaceutical royalties, the MSCI Life Sciences Indexes are designed to gauge the performance of pioneering companies within the biotech space.

These unique indexes can be used to benchmark growth, facilitate portfolio construction, and enhance investment research.

 

Source link

Continue Reading

Investment

Tesla shares soar more than 14% as Trump win is seen boosting Elon Musk’s electric vehicle company

Published

 on

 

NEW YORK (AP) — Shares of Tesla soared Wednesday as investors bet that the electric vehicle maker and its CEO Elon Musk will benefit from Donald Trump’s return to the White House.

Tesla stands to make significant gains under a Trump administration with the threat of diminished subsidies for alternative energy and electric vehicles doing the most harm to smaller competitors. Trump’s plans for extensive tariffs on Chinese imports make it less likely that Chinese EVs will be sold in bulk in the U.S. anytime soon.

“Tesla has the scale and scope that is unmatched,” said Wedbush analyst Dan Ives, in a note to investors. “This dynamic could give Musk and Tesla a clear competitive advantage in a non-EV subsidy environment, coupled by likely higher China tariffs that would continue to push away cheaper Chinese EV players.”

Tesla shares jumped 14.8% Wednesday while shares of rival electric vehicle makers tumbled. Nio, based in Shanghai, fell 5.3%. Shares of electric truck maker Rivian dropped 8.3% and Lucid Group fell 5.3%.

Tesla dominates sales of electric vehicles in the U.S, with 48.9% in market share through the middle of 2024, according to the U.S. Energy Information Administration.

Subsidies for clean energy are part of the Inflation Reduction Act, signed into law by President Joe Biden in 2022. It included tax credits for manufacturing, along with tax credits for consumers of electric vehicles.

Musk was one of Trump’s biggest donors, spending at least $119 million mobilizing Trump’s supporters to back the Republican nominee. He also pledged to give away $1 million a day to voters signing a petition for his political action committee.

In some ways, it has been a rocky year for Tesla, with sales and profit declining through the first half of the year. Profit did rise 17.3% in the third quarter.

The U.S. opened an investigation into the company’s “Full Self-Driving” system after reports of crashes in low-visibility conditions, including one that killed a pedestrian. The investigation covers roughly 2.4 million Teslas from the 2016 through 2024 model years.

And investors sent company shares tumbling last month after Tesla unveiled its long-awaited robotaxi at a Hollywood studio Thursday night, seeing not much progress at Tesla on autonomous vehicles while other companies have been making notable progress.

Tesla began selling the software, which is called “Full Self-Driving,” nine years ago. But there are doubts about its reliability.

The stock is now showing a 16.1% gain for the year after rising the past two days.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Investment

S&P/TSX composite up more than 100 points, U.S. stock markets mixed

Published

 on

 

TORONTO – Canada’s main stock index was up more than 100 points in late-morning trading, helped by strength in base metal and utility stocks, while U.S. stock markets were mixed.

The S&P/TSX composite index was up 103.40 points at 24,542.48.

In New York, the Dow Jones industrial average was up 192.31 points at 42,932.73. The S&P 500 index was up 7.14 points at 5,822.40, while the Nasdaq composite was down 9.03 points at 18,306.56.

The Canadian dollar traded for 72.61 cents US compared with 72.44 cents US on Tuesday.

The November crude oil contract was down 71 cents at US$69.87 per barrel and the November natural gas contract was down eight cents at US$2.42 per mmBTU.

The December gold contract was up US$7.20 at US$2,686.10 an ounce and the December copper contract was up a penny at US$4.35 a pound.

This report by The Canadian Press was first published Oct. 16, 2024.

Companies in this story: (TSX:GSPTSE, TSX:CADUSD)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Economy

S&P/TSX up more than 200 points, U.S. markets also higher

Published

 on

 

TORONTO – Canada’s main stock index was up more than 200 points in late-morning trading, while U.S. stock markets were also headed higher.

The S&P/TSX composite index was up 205.86 points at 24,508.12.

In New York, the Dow Jones industrial average was up 336.62 points at 42,790.74. The S&P 500 index was up 34.19 points at 5,814.24, while the Nasdaq composite was up 60.27 points at 18.342.32.

The Canadian dollar traded for 72.61 cents US compared with 72.71 cents US on Thursday.

The November crude oil contract was down 15 cents at US$75.70 per barrel and the November natural gas contract was down two cents at US$2.65 per mmBTU.

The December gold contract was down US$29.60 at US$2,668.90 an ounce and the December copper contract was up four cents at US$4.47 a pound.

This report by The Canadian Press was first published Oct. 11, 2024.

Companies in this story: (TSX:GSPTSE, TSX:CADUSD)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending

Exit mobile version